At the company’s direction, Malone said, their model mainly compared Zolgensma to the only other SMA treatment then on the market, a chronic treatment called Spinraza. It, too, was pricey ...
At the moment, the only other approved medicine for SMA is Biogen’s blockbuster SMA treatment Spinraza (nusinersen), so it will be interesting to see if Zolgensma’s availability has impacted ...
Hosted on MSN1mon
Biogen’s higher dose Spinraza under review by US and EU regulatorsSpinraza – approved in the US in 2016 and ... that may be a more convenient way of administration. Novartis’s Zolgensma (onasemnogene abeparvovec), approved in the US in 2019 and the EU ...
Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its ...
We think sales of Spinraza (partnered with Ionis) will remain around $2 billion, although competition from Novartis (gene therapy Zolgensma) and Roche (oral drug Evrysdi) has cut into growth.
Hosted on MSN11mon
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, ToddlersThe Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA (nusinersen ... treatment with Novartis AG’s (NYSE:NVS) Zolgensma (onasemnogene abeparvovec).
Patients can receive a single infusion of Zolgensma. The price of the drug was determined based on that for Spinraza, an existing drug. While Spinraza costs about 9.5 million yen per dosage and ...
Spinraza – approved in the US in 2016 and ... By contrast, Evrysdi and Zolgensma are expected to generate $2.78bn and $2.13bn in 2030, respectively.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results